Experts discuss optimizing NALIRIFOX treatment for metastatic pancreatic cancer, highlighting flexible dosing and early adverse event recognition for better patient outcomes.
Maen Abdelrahim, MD, PhD
Maen Abdelrahim, MD, PhD, is Section Chief of Gastrointestinal Medical Oncology at Houston Methodist Neal Cancer Center
Articles by Maen Abdelrahim, MD, PhD
Maen Abdelrahim, MD, PhD, discusses how to manage the dose of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma.